New study tests cancer drug in frail seniors
NCT ID NCT01642017
First seen Apr 14, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study tested the safety of the cancer drug pazopanib in frail elderly patients (75 and older) with metastatic solid tumors. Researchers aimed to find the highest safe dose by monitoring side effects during the first month of treatment. The study was terminated early after enrolling 18 patients, and results help guide future dosing in this vulnerable population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER (DIFFERENT SOLID TUMOUR TYPES) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre François BACLESSE
Caen, 14076, France
-
Centre Léon BERARD
Lyon, 69008, France
-
Hôpital Saint André
Bordeaux, 33075, France
-
Institut Claudius REGAUD
Toulouse, 31052, France
Conditions
Explore the condition pages connected to this study.